Sign in

Private company

Allena Pharmaceuticals, Inc.

American biological products company based in Newton, incorporated in Delaware2

In its 2022 annual report the company says: “We are a biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. We are focused on metabolic disorders that result in excess accumulation of certain metabolites that stimulate inflammation, damage the kidney, and potentially lead to chronic kidney disease, or CKD, and end-stage renal disease, or ESRD.”46

Last updated Oct 21, 2026.

Overview

  • IndustryBiological Products, (No Diagnostic Substances)2
  • HeadquartersNewton, United States2
  • Incorporated inDE3
  • Business address142 -F North Road, Suite 150, Sudbury, Ma 017763
  • Filer category, Emerging growth company3
  • Legal formCorporation2
  • LEI549300749HO5QS40BX972
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressC/O DELAWARE CORPORATE SERVICES INC., 19801 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 50005972

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income45678-$47.6M in 2021+97% since 2016
-$60.0M-$40.0M-$20.0M02016: -$24.2M-$24.2M20162017: -$20.9M-$20.9M2017−13%2018: -$35.6M-$35.6M2018+70%2019: -$47.5M-$47.5M2019+34%2020: -$32.0M-$32.0M2020−33%2021: -$47.6M-$47.6M2021+49%
Net income45678-$48.7M in 2021+242% since 2015
-$60.0M-$40.0M-$20.0M02015: -$14.2M-$14.2M20152016: -$24.5M-$24.5M2016+72%2017: -$21.6M-$21.6M2017−12%2018: -$35.6M-$35.6M2018+65%2019: -$47.3M-$47.3M2019+33%2020: -$32.8M-$32.8M2020−31%2021: -$48.7M-$48.7M2021+48%
Fiscal year20152016201720182019202020212022
Research and development$11.5M4$20.1M5$15.5M6$26.4M7$37.2M8$20.4M8$35.0M8
Operating expenses$47.6M8
Operating income-$24.2M4-$20.9M5-$35.6M6-$47.5M7-$32.0M8-$47.6M8
Income tax$06$06$06$07$08
Net income-$14.2M4-$24.5M5-$21.6M6-$35.6M7-$47.3M8-$32.8M8-$48.7M8

Compare Allena Pharmaceuticals, Inc. with another company

Corporate structure

Allena Pharmaceuticals, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Allena Pharmaceuticals, Inc.

  • Allena Pharmaceuticals, Inc. Newton, Massachusetts, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Allena Pharmaceuticals, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$2.1M8 Dec 31, 2021$1.5M8 Dec 31, 2020+43.0%
Accumulated depreciation$925.0K8 Dec 31, 2021$586.0K8 Dec 31, 2020+57.8%
Property and equipment, net$1.2M8 Dec 31, 2021$881.0K8 Dec 31, 2020+33.1%
Operating-lease assets (leased space)$455.0K8 Dec 31, 2021$678.0K8 Dec 31, 2020−32.9%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$30.0M8 Dec 31, 2021$35.0M8 Dec 31, 2020−14.4%

Leadership

Who has led Allena Pharmaceuticals, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Alexey L. Margolin2017–2018
  2. Louis Brenner Md.2019–2022

President

  1. Louis Brenner Md.2018–2022

Chief financial officer

  1. Edward Wholihan2017–2020
  2. Richard D. Katz2021–2022

Chief operating officer

  1. Louis Brenner Md.2018–2021
20202025
Board members and other officers (12)

Timeline

  1. Sep 7, 20228-K Listing notice or transfer27
  2. Sep 2, 20228-K Ended a material agreement; Bankruptcy or receivership; Listing notice or transfer28
  3. Aug 24, 20228-K Listing notice or transfer29
  4. Aug 11, 20228-K Other events30
  5. Aug 4, 20228-K Shareholder vote31
  6. Jul 12, 20228-K Entered a material agreement; Unregistered sale of shares; Change to shareholders' rights32
  7. Jul 11, 20228-K Entered a material agreement33
  8. Jul 8, 20228-K Results of operations; Other events34
  9. Jul 5, 20228-K Other events35
  10. Jun 28, 20228-K Ended a material agreement36
  11. Jun 22, 20228-K Ended a material agreement37
  12. May 4, 20228-K Entered a material agreement; Unregistered sale of shares; Change to shareholders' rights38
  13. Dec 4, 2019New chief executive Louis Brenner Md. becomes CEO12
  14. Jul 25, 2018Founded Allena Pharmaceuticals, Inc. is founded2
  15. Nov 1, 2017New chief executive Alexey L. Margolin becomes CEO13

Calendar

When it reported results

  1. Jul 8, 2022Reported quarterly or annual results34
  2. Jan 4, 2022Reported quarterly or annual results39
  3. Nov 10, 2021Reported quarterly or annual results40

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

51 filings to the SEC since October 2021: 3 annual reports, 5 quarterly reports, 18 major events, 3 insider forms, 4 large holders, 1 private raises, 17 other. The latest 20:

  1. Jun 12, 2023SEC STAFF ACTION EDGAR
  2. Feb 14, 2023SC 13G/A EDGAR
  3. Nov 14, 2022NT 10-Q EDGAR
  4. Sep 7, 20228-K EDGAR
  5. Sep 2, 20228-K EDGAR
  6. Aug 24, 20228-K EDGAR
  7. Aug 15, 202210-Q EDGAR
  8. Aug 11, 20228-K EDGAR
  9. Aug 4, 20228-K EDGAR
  10. Jul 13, 2022DEFA14A EDGAR
  11. Jul 12, 20228-K EDGAR
  12. Jul 12, 2022DEFA14A EDGAR
  13. Jul 11, 20228-K EDGAR
  14. Jul 11, 2022424B5 EDGAR
  15. Jul 8, 20228-K EDGAR
  16. Jul 5, 2022DEFA14A EDGAR
  17. Jul 5, 20228-K EDGAR
  18. Jun 28, 20228-K EDGAR
  19. Jun 23, 2022S-1 EDGAR
  20. Jun 22, 20228-K EDGAR

The 51 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

1 open-market trades by officers, directors and large owners since October 2021: 0 buys and 1 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Nov 15, 2021BRENNER LOUIS MDPresident and CEOSale40,328$0.81$32.7KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Money received by year$4.1M 2022–2022
Money received by yearMoney received by year, 2022–2022: $4.1M in all. Private raises (Form D) $4.1M.$0$2M$4M$6M2022 · Private raises (Form D): $4.1M2022
Figures by year
YearPrivate raises (Form D)Total
2022$4.1M$4.1M

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

  1. May 4, 2022Raised $4.1 million in a private offering of securities45 Form D: 5 investors so far Form D

SEC filer profile

How Allena Pharmaceuticals, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARAllena Pharmaceuticals, Inc.1
  • CIK0001624658
  • Employer ID (EIN)45-27299201
  • Filer status<br>emerging growth company1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)1
  • Business address142 -F North Road, Suite 150, Sudbury, MA 017761
  • Phone617-467-45771
  • Shares outstanding122,083,226 as of Aug 12, 202210
  • Public float$76.4M as of Jun 30, 202111
  • On EDGAR sinceNov 13, 20141
  • Filings289 in all: 8-K (77), 4 (53), SC 13G/A (20), 3 (19), SC 13G (16), 10-Q (15), 424B5 (13), DEFA14A (11)1
    All 32 form types

    CORRESP (7), S-8 (6), UPLOAD (6), 10-K (5), DEF 14A (5), FWP (5), EFFECT (4), 10-K/A (3), D (3), S-3 (3), 10-Q/A (2), DRS/A (2), PRE 14A (2), S-1 (2), 25-NSE (1), 424B4 (1), 8-A12B (1), CERTNAS (1), CT ORDER (1), DRS (1), DRSLTR (1), NT 10-Q (1), S-1/A (1), SEC STAFF ACTION (1)

  • Latest filingsAnnual report (10-K) Mar 31, 2022
    Quarterly report (10-Q) Aug 15, 2022
    Proxy statement (DEF 14A) May 24, 2022
    Latest 8-K (8-K) Sep 7, 2022

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
    SEC EDGAROther events
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
    SEC EDGAROther events
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46